Orchard Therapeutics to Webcast Conference Call of 2019 Financial Results

BOSTON and LONDON, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, February 27, 2020, at 8:00 a.m. ET to report its 2019 financial results and other business updates.

A live webcast will be available under "News & Events" in the Investors & Media section of the company's website at orchard-tx.com. The conference call can be accessed by dialing (866) 930-5155 (U.S. domestic) or +1-(409) 937-8974 (international) and referring to conference ID 8096875. A replay of the webcast will be archived on the Orchard website following the presentation.

About Orchard

Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically-modified blood stem cells and seeks to permanently correct the underlying cause of disease in a single administration. The company has one of the deepest gene therapy pipelines in the industry and is advancing seven clinical-stage programs across multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist, including inherited neurometabolic disorders, primary immune deficiencies and blood disorders.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit www.orchard-tx.com, and follow us on Twitter and LinkedIn.

Contacts

Investors

Renee Leck
Director, Investor Relations
+1 862-242-0764
[email protected]

You May Also Be Interested In

• Diversified Energy Reports Second Quarter 2026 Results
• The Board of Directors of FreightCar America, Inc. Adopts a Limited Duration Stockholder Rights Plan
• Sunrise Extends its Strategic Collaboration with Amdocs, Advancing its CRM Evolution with aOS